Pharmacokinetics, Mass Balance, and Biotransformation of [14C]tinengotinib, A Novel Multi-target Kinase Inhibitor, in Healthy Subjects-Reference-Cited by-同舟云学术

Pharmacokinetics, Mass Balance, and Biotransformation of [14C]tinengotinib, A Novel Multi-target Kinase Inhibitor, in Healthy Subjects

Published:2024-09-05 Issue: Volume: Page:
ISSN:1174-5886
Container-title:Drugs in R&D
language:en
Short-container-title:Drugs R D

Author:

Ni Shumao,Ma Sheng,Yu Yingying,Yu Zhenwen,Zhu Yujia,Sun Xiaofen,Li Lin,Sun Caixia,Wang Hui,Peng Peng,Gu Zheming,Zhang Hua,Wu Frank,Miao Liyan,Fan Jean^ORCID

Funder

TransThera Sciences (Nanjing), Inc.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40268-024-00486-2.pdf

Reference14 articles.

1. Peng P, Qiang XY, Li GY, Li L, Ni SM, Yu Q, et al. Tinengotinib (TT-00420), a novel spectrum-selective small molecule kinase inhibitor, is highly active against triple negative breast cancer. Mol Cancer Ther. 2022;22(2):205–14. https://doi.org/10.1158/1535-7163.MCT-22-0012.

2. Piha-Paul SA, Ileana-Dumbrava E, Janku F, Karp DD, Meric-Bernstam F, Rodon J, et al. Phase I study of TT-00420, a multiple kinase inhibitor, in patients with triple negative breast cancers and other advanced solid tumors. Cancer Res. 2020;80:3011. https://doi.org/10.1158/1538-7445.AM2020-3011.

3. Piha-Paul SA, Xu B, Janku F, Dumbrava EE, Fu S, Karp DD, et al. Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. J Clin Oncol. 2021;39:3090. https://doi.org/10.1200/JCO.2021.39.15_suppl.3090.

4. Al-Zahir MZ, AlAmeel T. Extrahepatic cholangiocarcinoma with prolonged survival: a case report. J Med Case Rep. 2017;11:357. https://doi.org/10.1186/s13256-017-1519-5.

5. Yang X, Wang YL, Zhao JK, Rong HH, Chen YJ, Xiong MT, et al. Coordinated regulation of BACH1 and mitochondrial metabolism through tumortargeted self-assembled nanoparticles for effective triple negative breast cancer combination therapy. Acta Pharma Sin B. 2022;12:3934–51. https://doi.org/10.1016/j.apsb.2022.06.009.